Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare Biotechnology
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious... see more

Recent & Breaking News (NDAQ:PULM)

Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock

PR Newswire January 30, 2019

Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire January 30, 2019

Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock

PR Newswire January 28, 2019

Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire January 28, 2019

Pulmatrix Announces $3.0 Million Registered Direct Offering

PR Newswire November 29, 2018

Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

PR Newswire November 21, 2018

Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology

PR Newswire November 15, 2018

Pulmatrix Reports Q3 2018 Results

PR Newswire November 14, 2018

Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress

PR Newswire September 17, 2018

Pulmatrix to Present at the 20th Annual Rodman & Renshaw Global Investment Conference on September 5, 2018

PR Newswire August 28, 2018

Pulmatrix Reports Q2 2018 Results

PR Newswire August 3, 2018

Pulmatrix Announces the Formation of the Pulmazole Clinical Advisory Board to Support Future Development

PR Newswire July 23, 2018

Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

PR Newswire June 25, 2018

Pulmatrix Announces Publication of Results from a Phase 1 Pharmacodynamic Study of PUR0200 in COPD Patients

PR Newswire June 13, 2018

Pulmatrix Announces Approval of Proposals Submitted to Company's Stockholders

PR Newswire June 7, 2018

Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San Diego

PR Newswire May 17, 2018

Pulmatrix Reports Q1 2018 Results

PR Newswire May 11, 2018

Pulmatrix to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017

PR Newswire September 21, 2017

Pulmatrix Receives Key Patents on its Inhaled Drug Delivery Technology and its COPD Drug

PR Newswire September 20, 2017

CEO Robert Clarke Discusses Positive Developments from Partnerships Obtained within the Past Few Months

GlobeNewswire September 19, 2017